We serve Chemical Name:(4-methylnaphthalen-1-yl)methylhydrazine CAS:887592-72-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-methylnaphthalen-1-yl)methylhydrazine
CAS.NO:887592-72-5
Synonyms:(4-methylnaphthalen-1-yl)methylhydrazine
Molecular Formula:C12H14N2
Molecular Weight:186.25300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.05000
Exact Mass:186.11600
LogP:3.20270
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (4-methylnaphthalen-1-yl)methylhydrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-methylnaphthalen-1-yl)methylhydrazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-methylnaphthalen-1-yl)methylhydrazine Use and application,(4-methylnaphthalen-1-yl)methylhydrazine technical grade,usp/ep/jp grade.
Related News: Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. (4-methylnaphthalen-1-yl)methylhydrazine manufacturer Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. (4-methylnaphthalen-1-yl)methylhydrazine supplier Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself. (4-methylnaphthalen-1-yl)methylhydrazine vendor Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. (4-methylnaphthalen-1-yl)methylhydrazine factory Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova.